Dylan Conklin
Overview
Explore the profile of Dylan Conklin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OBrien N, McDermott M, Conklin D, Luo T, Ayala R, Salgar S, et al.
Breast Cancer Res
. 2020 Aug;
22(1):89.
PMID: 32795346
Background: Combined targeting of CDK4/6 and ER is now the standard of care for patients with advanced ER+/HER2- breast cancer. However, acquired resistance to these therapies frequently leads to disease...
2.
Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
Campos M, Cohen M, Von Euw E, Velculescu V, Kujak J, Conklin D, et al.
JCO Precis Oncol
. 2019 Dec;
2.
PMID: 31799491
No abstract available.
3.
Welin E, Ngamnithiporn A, Klatte M, Lapointe G, Pototschnig G, McDermott M, et al.
Science
. 2018 Dec;
363(6424):270-275.
PMID: 30573544
The bis-tetrahydroisoquinoline (bis-THIQ) natural products have been studied intensively over the past four decades for their exceptionally potent anticancer activity, in addition to strong Gram-positive and Gram-negative antibiotic character. Synthetic...
4.
Papp E, Hallberg D, Konecny G, Bruhm D, Adleff V, Noe M, et al.
Cell Rep
. 2018 Nov;
25(9):2617-2633.
PMID: 30485824
To improve our understanding of ovarian cancer, we performed genome-wide analyses of 45 ovarian cancer cell lines. Given the challenges of genomic analyses of tumors without matched normal samples, we...
5.
OBrien N, Conklin D, Beckmann R, Luo T, Chau K, Thomas J, et al.
Mol Cancer Ther
. 2018 Feb;
17(5):897-907.
PMID: 29483214
The cyclinD:CDK4/6:Rb axis is dysregulated in a variety of human cancers. Targeting this pathway has proven to be a successful therapeutic approach in ER breast cancer. In this study, and...
6.
Fejzo M, Anderson L, Chen H, Guandique E, Kalous O, Conklin D, et al.
Genes Chromosomes Cancer
. 2017 Mar;
56(8):589-597.
PMID: 28316110
Poly (ADP-ribose) polymerase 1 (PARP1) is an enzyme involved in DNA repair under investigation as a chemotherapeutic target. Current randomized phase three trials of PARPi in metastatic breast cancer are...
7.
Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, et al.
Cancer Cell
. 2017 Feb;
31(2):225-239.
PMID: 28196595
Cancer cell lines are major model systems for mechanistic investigation and drug development. However, protein expression data linked to high-quality DNA, RNA, and drug-screening data have not been available across...
8.
Hurvitz S, Kalous O, Conklin D, Desai A, Dering J, Anderson L, et al.
Breast Cancer Res Treat
. 2015 Feb;
149(3):669-80.
PMID: 25663547
Everolimus (RAD001, Afinitor(®)) is an oral, selective mTOR inhibitor recently approved by the US-FDA in combination with exemestane for treatment of hormone receptor positive advanced breast cancer. To date, no...
9.
OBrien N, McDonald K, Tong L, Von Euw E, Kalous O, Conklin D, et al.
Clin Cancer Res
. 2014 Jun;
20(13):3507-20.
PMID: 24879796
Purpose: Altered PI3K/mTOR signaling is implicated in the pathogenesis of a number of breast cancers, including those resistant to hormonal and HER2-targeted therapies. Experimental Design: The activity of four classes...
10.
Kalous O, Conklin D, Desai A, Dering J, Goldstein J, Ginther C, et al.
Breast Cancer Res Treat
. 2013 Oct;
141(3):397-408.
PMID: 24091768
Aurora kinases play important roles in cell division and are frequently overexpressed in human cancer. AMG 900 is a novel pan-Aurora kinase inhibitor currently being tested in Phase I clinical...